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Abstract: Measurement error in self-reported sugars intake may explain the lack of
consistency in the epidemiologic evidence on the association between sugars and disease
risk. This review describes the development and applications of a biomarker of sugars intake,
informs its future use and recommends directions for future research. Recently, 24 h urinary
sucrose and fructose were suggested as a predictive biomarker for total sugars intake, based
on findings from three highly controlled feeding studies conducted in the United Kingdom.
From this work, a calibration equation for the biomarker that provides an unbiased measure
of sugars intake was generated that has since been used in two US-based studies with
free-living individuals to assess measurement error in dietary self-reports and to develop
regression calibration equations that could be used in future diet-disease analyses. Further
applications of the biomarker include its use as a surrogate measure of intake in diet-disease
association studies. Although this biomarker has great potential and exhibits favorable
characteristics, available data come from a few controlled studies with limited sample sizes
conducted in the UK. Larger feeding studies conducted in different populations are needed to
further explore biomarker characteristics and stability of its biases, compare its performance,
and generate a unique, or population-specific biomarker calibration equations to be applied
in future studies. A validated sugars biomarker is critical for informed interpretation of
sugars-disease association studies.
Keywords: sugars; diet; predictive biomarker; urine; sucrose; fructose; measurement error;
validation; calibration
1. Introduction
Measurement error (ME) in self-reported diet has been a long-standing obstacle for determining the
true association between sugars and chronic disease risk. While the evidence for sugars’ association
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with dental caries [1] and weight gain [2–4] has been rather consistent, the link to cardiovascular
disease (CVD) [5–8], type 2 diabetes [9,10] and cancer [6,11–15] has been ambiguous and inconclusive.
Although added sugars consumption in the United States (US) has declined over the last ten years,
it still remains high, particularly among children (17% of energy intake [EI]) and young adults
(16% EI) [16,17]. However, despite the high prevalence of this behavior and its implicated adverse
effects on health, the inconsistency in evidence obtained from large prospective studies and randomized
controlled trials has hindered the setting of a specific and unique recommendation on sugars intake in
the US [18–20]. Sugars comprise monosaccharides (glucose, fructose, galactose) and disaccharides
(sucrose, maltose, lactose), and their sum is known as “total sugars.” Sugars that are naturally occurring
in fruits, vegetables, and dairy products only partly account for total sugars intake, whereas sugars
from highly processed food and drinks, added during food processing and preparation or at the table,
have become more significant contributors of total sugars intake [21]. As a source of empty calories
and a common ingredient of unhealthy foods, sugars are among the nutrients that are frequently
misreported [22,23]. It is highly plausible that ME in self-reported sugars may be obscuring the
true relationship between sugars and disease risk and may explain the lack of consistency in the
epidemiologic evidence. Development of novel approaches for obtaining more accurate estimates of
intake, independent of self-reported diet, is crucial for attaining more valid and reliable risk estimates
for sugars in relation to chronic disease risk. Until then, it is uncertain whether the lack of association is
due to our inability to measure sugars accurately or to a genuine lack of an association between sugars
and disease risk.
Dietary biomarkers hold a lot of promise as objective measures of intake in diet-related studies. Thus
far, four categories have been described based on biomarkers’ characteristics: recovery, predictive,
concentration, and replacement biomarkers [24]. They have multiple applications, including (1) in
dietary validation studies, to characterize ME in dietary self-reports [25,26]; (2) in calibration studies
nested within prospective cohorts, to develop calibration equations for “correcting” self-reported intake
in the main studies [27–29]; (3) in population studies with available biological samples, as measures
of dietary exposure, either alone [30–33] or in combination with self-reports [34,35]; and (4) in dietary
intervention studies as measures of compliance [36].
2. Development of the 24 h Urinary Sucrose and Fructose Biomarker
2.1. Preliminary Work
Early work has shown that under physiological conditions, small amounts of dietary sucrose [37]
and fructose [38] are excreted in the urine. During digestion, sucrase hydrolyzes sucrose into
glucose and fructose in the brush border of the duodenum. Although healthy gastrointestinal mucosa
is relatively impermeable to disaccharides, under physiological conditions, very small amounts of
unhydrolyzed dietary sucrose may pass the intact intestinal wall, probably by a process of non-mediated
diffusion [37], and once in the circulation, sucrose is readily excreted in urine [39]. Fructose is absorbed
unchanged in the lower part of duodenum and jejunum; it is passively transported by a fructose-specific
facilitative transporter (GLUT5) across the apical membrane of the intestinal epithelial cells and by
a facilitative transporter for glucose and fructose (GLUT2) across the basolateral membrane into the
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circulation [40,41]. The amount of fructose occurring in urine is probably a fraction of the dietary
fructose or fructose derived from sucrose that escapes the uptake by the liver, as the main site of fructose
metabolism, and by other tissues, such as kidneys, adipose tissue and skeletal muscle [42,43], and that
escapes the reabsorption in the renal tubules [41]. Considerable amounts of fructose were detected in
urine after ingesting sucrose in a bolus [38]. Although some amount of glucose can be measured in urine,
it appears to be person-specific and is not reflective of dietary intake due to insulin-controlled glucose
reabsorption occurring in the kidneys.
The preliminary work on sucrose and fructose as potential biomarkers of sucrose intake was
conducted by Luceri et al. [44], based on data from nine participants consuming a “regular Italian”
diet for a week and a low-sucrose diet for three days. Sucrose and fructose were measured in spot
urine samples collected within 2 h of breakfast, lunch, and dinner on the last day of each study diet.
Sucrose and fructose excretion during the low-sucrose diet was significantly lower compared than the
excretion during the regular diet. Furthermore, the sucrose content of both the low-sucrose and regular
diet, as assessed by a food diary, was significantly associated with the post-meal urinary excretion of
sucrose and fructose. As the slopes of the regression lines calculated from the regression models for the
low-sucrose and regular diet were similar, a common slope for the association between sucrose intake
from low-sucrose or regular diet and sucrose excretion was calculated (β = 0.26; SE = 0.08). Similarly,
a common slope for the association between sucrose intake from low-sucrose or regular diet and fructose
excretion was reported (β = 0.15; SE = 0.05). No correlation was found between the urinary excretion
of glucose and intake of sucrose. The findings from this study implied that sucrose and fructose may
have the potential to be used as biomarkers of sugars consumption, however further work was needed to
study the characteristics of the biomarker and to develop prediction equations based on a daily diet and
against true intake.
2.2. Development of the Urinary Sugars Biomarker under Controlled Conditions
Urinary sugars as potential sugars biomarkers were then rigorously investigated under highly
controlled conditions in two feeding studies conducted in the United Kingdom [45]. All dietary intake in
these studies was known, and multiple 24 h urine samples were collected and verified for completeness
using the para-amino benzoic acid (PABA) test [46]. The first study was a 30-day randomized cross-over
design study involving 12 healthy males aged 25–77 years. In randomized order, all participants
consumed low (63 g), medium (143 g), and high (264 g) total sugars diet over three 10 day dietary
periods, respectively; this level of intake corresponded to the lower and upper 2.5 percentiles and median
total sugars intake for the adult UK population [47]. All foods consumed by the participants were
prepared in a metabolic kitchen, and no foods or drinks obtained outside the metabolic suite were allowed
to be consumed. On Days 4–7 during each 10-d dietary period, participants collected 24 h urine samples,
which were analyzed for sucrose and fructose. Although the within-subject variability of sucrose and
fructose excretion was rather high in these 12 participants at the same level of total sugars intake, the
mean urinary sucrose and fructose increased across the increasing levels of sugars consumption over
the three dietary periods, and there was a significant difference in the mean excretion of both sucrose
(p < 0.001) and fructose (p < 0.001) between the three diets. Given that the dose-response association
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between the diet and sugars excretion improved after combining urinary sucrose and fructose, their sum
was further investigated as a potential biomarker.
The 2nd feeding study assessed the performance of the biomarker in subjects consuming their
usual diets over an extended period of time, i.e., simulating normal dietary behavior under controlled
conditions [45]. Seven male and six female participants aged 23–66 years consumed their habitual diet
(previously assessed by four consecutive 7-day diet records), and collected 24 h urine samples daily over
30 days while residing in a metabolic suite. All the foods consumed by the participants were prepared in
the metabolic kitchen, where the foods were weighed to the nearest gram and left-overs weighed out upon
return. The group 30 day mean sum of the 24 h urinary sucrose and fructose (24uSF) was 98 mg/day
(range 25.4–267.5 mg/day), which represented a very low proportion of their 30 day mean total sugars
intake (approximately 0.05%), yet, the two were highly correlated (r = 0.84; p < 0.001). The 24uSF
was also highly correlated to sucrose intake (r = 0.77; p = 0.002). In the linear regression of urinary
to dietary sugars, true total sugars intake explained 72% of the variability in the sucrose and fructose
excretion, revealing sugars intake as a strong determinant of sucrose and fructose excretion [45]. The
mean correlation between 24uSF measured from single 24 h urine and the “usual” total sugars intake
was 0.71 [48]. In this study, the 30 day mean 24uSF was significantly correlated to the 30 day mean
intake of extrinsic sugars (i.e., any sugars or syrups added during processing and preparation of foods
and drinks or added at the table, including sugars from fruit juices and honey.) (r = 0.84; p < 0.001)
but not intrinsic sugars (i.e., any sugars from fruits and vegetables (excluding fruit juices) and cereal and
cereal products (excluding breakfast cereals, biscuits, cakes, sweet buns, pies, flans, pastries, scones,
and cereal-based puddings)) (r = 0.43; p = 0.144) [49]. Nonetheless, this study was not designed to
investigate the performance of urinary sugars as dietary biomarkers of extrinsic vs. intrinsic sugars.
The stronger correlation observed with extrinsic sugars may have been due to the fact that the intake of
intrinsic sugars in these 13 subjects was lower and narrower in range (68 ˘ 23 (SD) g/day) than was
their extrinsic sugars intake (123 ˘ 41 (SD) g/day).
To investigate the effect of body mass index (BMI) on the performance and validity of the biomarker,
Joosen et al. [50] compared the biomarker’s response to diets providing 13%, 30%, and 50% energy
from total sugars, in a randomized cross-over design under controlled conditions, in 10 normal-weight
and nine obese participants living in a metabolic suite over 12 days. The excretion of both sucrose and
fructose in urine increased to a similar degree in both the normal-weight and obese participants with the
increase in total sugars intake; no significant interaction effect of BMI on urinary sucrose (p = 0.65) or
fructose (p = 0.55) was observed. These findings have lent support to the application of this biomarker
as a valid measure of intake in participants regardless of their BMI, as well as to investigations of the
relationship between the consumption of sugars and the risk of obesity.
Given that the sugars biomarker exhibited a high correlation to “true” intake and was related to intake
in a dose-response and time-sensitive manner, yet was recovered in a very low proportion in urine, 24uSF
was categorized into a new class called “predictive” biomarkers [45]. Unlike recovery biomarkers, which
are gold standard reference instruments, free of bias [51], predictive biomarkers contain a certain level of
person-specific, intake-related, and covariate-related bias [52]. However, for these measures to qualify
as predictive biomarkers, their biases should not explain a significant proportion of the variability in
the biomarker, should be stable between individuals and across populations, and be estimable from a
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feeding study. Once those biases have been estimated, they can be applied to “correct” or “calibrate”
the biomarker that can then serve as a reference instrument [52]. Such an equation for “calibrating” the
24uSF biomarker was generated from the 2nd UK feeding study [45,52]. The equation describes the
association between the 24uSF and “true” total sugars intake, quantifies the biases associated with the
24uSF biomarker, and “calibrates” the biomarker to provide an unbiased measure of intake:
M˚ij “Mij ´ 1.67´ 0.02ˆ Si ` 0.71ˆ Ai (1)
where Mi˚j is the log-transformed calibrated sugars biomarker, Mij is the log-transformed biomarker,
Si is an indicator variable that equals 0 for men and 1 for women, and Ai is the log-transformed age
in years. The calibrated biomarker Mi˚j satisfies the following ME model for predictive biomarkers:
Mi˚j “ Ti ` uMi ` εMij , where Ti is the log-transformed true usual intake of total sugars, uMi is a
person-specific bias, and εMij is a within-person random error [52]. Assuming that these biases are
similar between individuals and across populations, this biomarker calibration equation can be applied
in other studies with available 24 h urine collections to “calibrate” the sugars biomarker to be used
as a reference instrument for total sugars intake. If spot urines, rather than 24 h urine collections,
are available in population studies, the biomarker “calibration” equation cannot be applied to provide
an unbiased measure of intake, however, the biomarker can be used as a correlate to intake, i.e.,
concentration biomarker.
2.3. Investigation of Urinary Fructose as a Biomarker against Self-Report in Children
Johner et al. [53] investigated the use of urinary fructose as a biomarker of sugars intake among
children in a subsample from the Dortmund Nutritional and Anthropometric Longitudinally Designed
(DONALD) study. The analysis included 58 boys and 56 girls with mean age of 9.3 ˘ 0.8 and
7.9 ˘ 0.7 years, respectively, with available 24 h urinary fructose and self-reported diet data. Total
sugars intake assessed by a three day weighed food record was significantly associated with fructose
excretion from a single 24 h urine (r = 0.43; p < 0.001); each gram of total sugars intake was associated
with a 0.9% increase in the amount of 24 h urinary fructose. The R2 for the observed association was
low (R2 = 0.18), most probably due to the availability of a single-day urinary measurement, which would
have introduced considerable random error in the biomarker, and to the use of a self-reported diet. Based
on the authors’ preliminary data, in which a less consistent dose-response relationship between sucrose
intake and excretion was found, urinary sucrose was omitted from the analysis [53]. In contrast to
previous studies [44,45], no preservative was used to preserve the 24 h urine collection but the urine was
only refrigerated, which may have led to sucrose hydrolysis and thus to unreliability of the sucrose data.
The lower correlation for fructose excretion observed by Johner et al. [53] may also have been partly due
to fructose degradation or uptake by bacteria in preservative-free urine, in case of noncompliance with
the storage instructions of their 24 h urine collection protocol.
3. Application of the Urinary Sugars Biomarker in Validation and Calibration Studies with
Free-Living Individuals
Acknowledging the impact of ME, researchers have started conducting dietary validation studies with
available biomarkers to assess ME in dietary self-reports [25,54]. They have also begun incorporating
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calibration substudies within their cohorts to develop regression calibration equations [27–29] that could
then be applied to calibrate self-reported intake, i.e., predict unbiased intake in all cohort participants to
obtain more reliable risk estimates in diet-disease analyses [55–60].
The urinary sugars biomarker has recently been applied in two US biomarker-based studies, the
Observing Protein and Energy Nutrition (OPEN) study [52] and the Nutrition and Physical Activity
Assessment Study (NPAAS) [61]. The OPEN study involved 484 participants aged 40–69 years recruited
from Montgomery County, MD, in 1999 and 2000 [62]. The NPAAS is a biomarker study embedded in
the Women’s Health Initiative (WHI) Observational Study (n = 93,676), involving 450 postmenopausal
women aged 50–79 years at baseline, recruited from nine WHI centers between 2007 and 2009 [27].
Participants from both studies completed a food frequency questionnaire (FFQ) and at least two
24 h dietary recalls (24HR), and the NPAAS participants additionally completed a four-day food record
(4DFR). The 24uSF biomarker and doubly-labeled water, a biomarker for energy intake, were measured
in both studies, with an aim to investigate ME in self-reported total sugars (g/day) and total sugars
density (g/1000 kcal). Given that the 24uSF biomarker has been found to contain a certain amount of
bias that has been estimated in a feeding study, the biomarker was first “calibrated,” using the biomarker
“calibration” equation (Equation (1)) previously described [52], to provide an unbiased measure of total
sugars intake. These applications assume that the biases in the biomarker are stable across different
populations. Once “calibrated,” the biomarker was applied to the OPEN and the NPAAS data as a
reference instrument to assess the ME in self-report instruments by estimating the Attenuation Factor
(AF) and the correlation between true and self-reported intake. AF represents the slope in the regression
of true on reported intake and measures the attenuation (underestimation) of the disease risk due to ME
in self-reported intake, where observed relative risk (RR) = true RRAF [63]. AF can have values between
0 and 1; AF = 1 would indicate no attenuation, whereas as AF gets closer to 0, the extent of attenuation
increases. Table 1 reports the AFs for the instruments used in the OPEN and NPAAS, and the observed
disease RR associated with self-reported sugars measured with error when true RR = 2. For absolute
sugars, the AF for the FFQ was lower (less favorable) than the AFs for the average of two or three
24HRs, and, in the OPEN study, for both the 24HR and FFQ, the AFs were lower in women than in men.
For sugars density, the AF for the FFQ was somewhat lower than for the 24HR and was lowest (least
favorable) for the 4DFR.
Another estimate of ME in dietary self-report is the correlation between true and self-reported intake,
calculated based on the ME model parameters of the biomarker and self-reports [63]. The correlation
between the true and self-reported total sugars density in the OPEN participants was 0.5 for the FFQ and
a single 24HR, and 0.6 for the average of two 24HRs in men, and 0.2 and 0.3 in women respectively [52].
The correlation between the true and self-reported total sugars density in the NPAAS women was of a
similar magnitude to the correlation observed in the OPEN women, and was 0.3 for the FFQ, a single
24HR, and the average of two 24HRs, 0.4 for average of three 24HRs, and 0.2 for the 4DFR [61]. Based
on the ME estimates from these two studies, women misreported sugars consumption more than men,
and even though all investigated self-reporting instruments were associated with substantial ME, the
average of multiple 24HRs was found to perform the best [52,61].
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Table 1. Attenuation factors (AF) for self-reported total sugars in the OPEN and NPAAS
studies from a measurement error model with urinary sugars biomarker as a reference
instrument and observed relative risk (RR) for true RR = 2 [52,61].
OPEN NPAAS
Men Women Women
FFQ 24HR : FFQ 24HR : FFQ 24HR ; 4DFR
Total sugars (g/day)
AF 0.28 0.41 0.17 0.29 0.22 0.34 0.33
Obs RR (true RR = 2) 1.21 1.33 1.13 1.22 1.16 1.27 1.26
Total sugars density
(g/1000 kcal)
AF 0.39 0.41 0.33 0.35 0.48 0.57 0.32
Obs RR (true RR = 2) 1.31 1.33 1.26 1.27 1.39 1.48 1.25
Obs—Observed; FFQ—Food frequency questionnaire; 24HR—24 h dietary recall; 4DFR—4 day food record;
:: The average of two 24HRs; ;: The average of three 24HRs.
Next, using the 24uSF biomarker in the NPAAS, regression calibration equations for total sugars
(g/day) and total sugars density (g/1000 kcal) were derived by regressing the “calibrated” 24uSF
biomarker, i.e., unbiased intake, on the FFQ-reported total sugars intake and the baseline characteristics,
which were found to be significant predictors of unbiased intake [61]. These calibration equations
also allow an investigation of various baseline characteristics, known to be associated with dietary
misreporting, as potential predictors of true intake, given the ME in the self-report [27,28]. These
regression calibration equations can be used to “correct” the FFQ sugars and sugars density intake for
ME in all WHI participants in future WHI association studies of sugars and disease risk to obtain more
reliable risk estimates. The derived equations are as follows: regression calibration equation for total
sugars, g/day: log-true intake = 3.51 + 0.23 ˆ log FFQ + 0.17 ˆ log Age ´ 0.11 ˆ log BMI ´ 0.64 ˆ
current smoker + 0.55 ˆ < high school (HS) graduate + 0.30 ˆ HS graduate + 0.16 ˆ some college +
0.04 ˆ square-root metabolic equivalents/week; regression calibration equation for total sugars density,
g/1000 kcal: log-true density = 0.49 + 0.44 ˆ log FFQ + 0.77 ˆ log Age ´ 0.37 ˆ log BMI ´ 0.56 ˆ
current smoker + 0.64 ˆ < HS graduate + 0.43 ˆ HS graduate + 0.18 ˆ some college.
4. Application of the Urinary Sugars Biomarker as a Measure of Dietary Exposure in
Diet-Disease Association Studies
The urinary sugars biomarker has so far been used as a surrogate measure of intake in two analyses of
the Norfolk arm of the European Prospective Investigation into Cancer (EPIC) investigating the effect of
sugars consumption on obesity risk [32,33]. Given only spot urine samples were collected in this study
population, the biomarker calibration equation could not be applied to obtain unbiased estimates of total
sugars intake. Therefore, the biomarker was used as a concentration biomarker.
The first analysis was a cross-sectional investigation involving 404 obese (BMI > 30 kg/m2) and
471 normal-weight (BMI < 25 kg/m2) participants from the EPIC-Norfolk aged 45–75 years [32].
Participants in the highest vs. lowest quintile for the biomarker (i.e., the ratio of urinary sucrose to
fructose measured in spot urine) were at 2.4 times higher risk of being obese (age- and gender-adjusted
OR = 2.44, 95% CI = 1.54–3.86; ptrend < 0.001). The risk of obesity was also positively associated with
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sucrose measured in spot urine (ORQ5vs.Q1 = 1.82, 95% CI = 1.26–2.85; ptrend = 0.02). A non-significant
inverse association between sugars intake and obesity risk was observed when FFQ-measured total
sugars (ORQ5vs.Q1 = 0.89, 95% CI = 0.54–1.43; ptrend = 0.4) or the ratio of FFQ-measured sucrose
to fructose (ORQ5vs.Q1 = 0.77, 95% CI = 0.48–1.25; ptrend = 0.3) were used as measures of sugars
intake. Given that creatinine was highly correlated with BMI, and could not be used to adjust for urine
concentration, the authors used the ratio of sucrose to fructose in urine as a measure of intake.
In the second more recent analysis involving 1734 participants from the EPIC-Norfolk aged
39–77 years, the BMI measured at baseline and after 3 years of follow-up was positively associated
with urinary sucrose from spot urine, and inversely associated with self-reported sucrose intake assessed
by a seven day diet record (7DR), FFQ or 24HR collected at baseline [33]. Participants in the highest
vs. lowest quintile of urinary sucrose were 1.54 times more likely to become overweight or obese
(ORQ5vs.Q1 = 1.54, 95% CI = 1.12–2.12; ptrend = 0.008), whereas those in the highest vs. lowest quintile
of 7DR-based sucrose intake were at 44% lower risk of becoming overweight or obese (ORQ5vs.Q1 = 0.56,
95% CI = 0.40–0.77; ptrend < 0.0001) after three years of follow-up. The authors used urinary sucrose
per specific gravity to control for urine concentration, rather than the ratio of urinary sucrose to fructose,
due to their having fewer available samples with both sucrose and fructose values within the acceptable
analytical range. However, in sensitivity analyses in a reduced sample that used the sucrose to fructose
ratio as a biomarker, all risk estimates remained virtually unchanged. Available evidence has consistently
linked increased sugars consumption with an increase in obesity risk [2–4]. In this population, such an
association was detected when using urinary sugars from spot urine as a concentration biomarker but not
when using self-reported intake.
5. Summary and Future Research
Applying a sugars biomarker in future diet-disease association studies is crucial for detecting unbiased
disease-risk estimates for sugars consumption. Biomarkers have been successful in revealing diet and
disease associations that otherwise have been difficult to ascertain. Energy intake has been found to be
associated with increased risk of breast cancer [58], all-cancer [56], CVD [57] and type 2 diabetes [60];
and protein intake with risk of type 2 diabetes [60] and frailty [64]; using biomarker-calibrated self-report
estimates but not using un-calibrated instruments. When biomarkers are collected for all participants,
they can also be used as surrogate measures of intake in relation to disease, either alone [30–32] or
in combination with self-reports [34,35]. High sugars consumption was associated with statistically
significant increased risk of obesity when the urinary sugars biomarker was used as a measure of
dietary exposure [32,33], whereas no association [32] or inverse association [33] was found when using
self-reported intake.
Although the 24uSF biomarker has been developed under highly controlled conditions, has great
potential, and exhibits considerably favorable characteristics for a biomarker, available data come from
only a few controlled studies with limited sample sizes (n = 12, n = 13, n = 19) [45,50]. Data
from these feeding studies showed that the biomarker contains bias, which may originate from the
between-subject variability in sucrose and fructose absorption, fructose uptake by individual tissues
or reabsorption in the kidneys, and may be determined by genetic, dietary or lifestyle factors, or
physiological or medical conditions. Some variability may be due to the analytical methods or issues
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related to urine collection, processing or storage. Increased sucrose excretion has long been used as
a marker of altered gastrointestinal permeability [65,66], attributed to either structurally damaged or
inflamed mucosa occurring in gastroduodenal, celiac [67] or inflammatory bowel disease [68], or the
presence of congenital sucrose-isomaltose deficiency, which is considered to be particularly rare [69,70].
The intake of certain medications (e.g., non-steroid anti-inflammatory drugs [NSAID] [71], proton pump
inhibitors [72]) and alcohol have also been associated with increased gastrointestinal permeability [73],
while smoking has been found to decrease permeability, and to reduce the adverse effect of NSAID
and alcohol on the gastrointestinal mucosa during simultaneous exposure, possibly by protecting the
intercellular tight junctions of the epithelium [73,74]. Intestinal inflammation and infection leads to
decreased expression of GLUT5, a fructose-specific transporter in the brush border membrane, and
thus may impair fructose absorption [41]. Although, GLUT5 is acutely and efficiently upregulated
by fructose concentration in the intestinal lumen and facilitates absorption, fructose malabsorption
has been shown to occur among healthy individuals at fructose doses higher than 15 g, particularly
in presence of low luminal glucose concentration, as glucose significantly improves fructose transport
through enterocyte [41,75].
In the applications of the biomarker “calibration” equation in the US-based studies [52,61], an
assumption was made that the biomarker’s biases are stable across participants and across different
populations, which may not hold and needs to be further investigated. The original feeding study,
the source of the urinary sugars “calibration” equation, was conducted in the UK [45]. Total sugars
composition in the UK diet differs from sugars composition in the diet in the US and other countries.
In the UK, table sugar or disaccharide sucrose is the main caloric sweetener, while in the US,
monosaccharide sweeteners (e.g., fructose, glucose, dextrose) derived primarily from corn represent
more than half of the caloric sweeteners used in the food supply [76,77]. A significantly different
sucrose to fructose ratio in the US diet may result in different levels of sucrose and fructose measured
in urine. The presence of glucose in the intestinal lumen enhances fructose absorption [75]. Hence,
consuming fructose as part of sucrose or from a diet with a similar content of glucose may result in higher
fructose absorption and thus excretion. Therefore, the performance and applicability of the calibration
equation for the 24uSF developed with the UK diet requires further investigation and validation among
US participants. We need further highly-controlled studies conducted in different populations across
geographical regions to further explore biomarker characteristics and the stability of its biases, compare
its performance, and validate the existing calibration equation for the 24uSF, or, if more applicable,
generate population-specific biomarker calibration equations to be applied in future studies. Obtaining
large sample sizes (n > 100) in future controlled studies will be crucial for achieving precision in
estimating the biases arising from between-subject variability and for reliably investigating their effect
on biomarker performance (personal communications, L. Freedman). Preparing and analyzing duplicate
diets in such studies will avoid introducing ME from food composition tables in the estimate of “true
intake” and will further increase the precision of the biomarker calibration equations. Although ensuring
completeness of urine collections may not be necessary in population-based biomarker studies [78], it
is essential in controlled feeding studies. Misestimation of the 24 h urinary biomarker excretion due
to incomplete urine collections may affect the biomarker calibration equation and thus may lead to
errors in the estimation of unbiased sugars intake in future biomarker studies. Preserving 24 h urine
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during collection is required for maintaining the stability of the sucrose and fructose [48], and boric
acid in a concentration of ď2 g/L has so far been used [45]. Among the analytical methods applied
to measure sucrose and fructose in urine, liquid chromatography and gas chromatography with mass
spectrometry (LC/MS and GC/MS) techniques use low-cost consumables, however, require expensive
instrumentation and technical expertise [79]. In addition, for the GC and GC/MS analytical approaches,
the sample-preparation step is labor intensive and time consuming [79,80], whereas the colorimetric
method can be easily set up in most laboratories and is compatible with boric acid as a preservative [45].
Due to large participant burden, complex logistics, and high costs, collection of 24 h urine samples is
not always feasible in large population studies. Investigation of the utility of spot urines in assessment
of sugars intake is much needed and would undoubtedly lead to findings that could have major practical
implications for epidemiologic studies. The urinary sucrose and fructose biomarker is a short-term
measure of intake excreted 2–6 h after ingestion [44], and so when measured in spot urine, the biomarker
(besides its inherent biases) will also contain a certain amount of ME, depending on the timing of the
spot urine collection relative to intake. In the scenario of a population study, these errors will be expected
to attenuate the association between true intake and the biomarker and to make it unstable. Hence, when
measured in spot urine, this biomarker may possibly be used as a concentration, rather than as a predictive
biomarker. Further investigation under controlled conditions, and identification of determinants of errors
associated with the sugars biomarker measured in spot urine, will inform its future applications as an
unbiased instrument. The concentration of sucrose and fructose in partial collections has been shown to
correlate well with total sugars intake [44] and has been used previously as surrogate measures of intake,
showing a positive association with obesity risk in a population study [32,33], consistent with the current
evidence [2–4].
Recently, the carbon stable isotope ratio (13C/12C, expressed as δ13C) was proposed as a biomarker of
sugars intake in populations consuming sugars abundant with 13C, such as corn-based sugars and sugar
cane [81–83]. Although measuring component-specific δ13C, such as δ13C in red blood cell alanine, has
shown much promise [84], this biomarker has never been investigated under highly-controlled conditions
of a feeding study. Investigating the comparative performance of the urinary sugars biomarker and δ13C
in relevant populations under controlled conditions would be particularly useful. Furthermore, a panel
of four urinary biomarkers (formate, citrulline, taurine and isocitrate) indicative of sugar-sweetened
beverage consumption has been identified using a metabolomics-based approach, and further work needs
to be conducted to define their use in population-based research [85].
The urinary sugars biomarker has so far been used in observational studies only. One of the
critical limitations of intervention studies investigating the effect of sugars consumption has been
the reliance on self-reported measures [5], thus application of the sugars biomarker as a measure of
intervention compliance will inform the interpretation of findings and help obtain valid estimates of the
intervention effect.
Methodologically rigorous development of the urinary sugars biomarker and its applications in
population-based studies has shown that this biomarker exhibits favorable characteristics for a biomarker
and has great potential, yet further investigation is needed to better characterize and inform its application
in different populations. A validated sugars biomarker that can be applied in available and future
observational and intervention studies with biological samples will serve as an instrumental resource
Nutrients 2015, 7 5826
that would allow correction for ME in self-reported sugars and detection of unbiased sugars-disease
associations. Until strong and consistent evidence for adverse health effects of sugars is found, no firm
advice can be given to the general public.
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